低剂量吸入一氧化氮治疗对自主呼吸与插管COVID-19患者的影响:一项回顾性倾向匹配研究
该多中心回顾性研究纳入2020年3月至2022年6月Mayo Clinic各院区SCCM VIRUS COVID-19登记库中需要HFNC、NIV或IMV的COVID-19患者2767例,其中自主呼吸组1879例(153例接受iNO)、插管组888例(193例接受iNO),采用倾向评分匹配和IPTW分析结局。结果显示两组使用iNO后48小时内FiO2需求、P/F比值和呼吸频率均有改善;自主呼吸组使用iNO未显著改变插管风险(PSM OR 1.08,CI 0.71-1.65;IPTW OR 1.10,CI 0.90-1.33),但院内死亡风险降低(PSM HR 0.49,CI 0.32-0.75;IPTW HR 0.40,95%CI 0.26-0.62),插管组无此关联(PSM HR 0.90,CI 0.66-1.24;IPTW HR 0.98,95%CI 0.73-1.31)。iNO使用与住院时间、ICU停留时间、通气时间延长及肌酐升高发生率增加相关。
要点
- 自主呼吸COVID-19患者使用iNO后院内死亡风险降低:PSM HR 0.49(CI 0.32-0.75),IPTW HR 0.40(95%CI 0.26-0.62)。
- 插管COVID-19患者使用iNO未见院内死亡风险降低:PSM HR 0.90(CI 0.66-1.24),IPTW HR 0.98(95%CI 0.73-1.31)。
- 自主呼吸患者使用iNO未显著改变插管风险:PSM OR 1.08(CI 0.71-1.65),IPTW OR 1.10(CI 0.90-1.33)。
- 自主呼吸与插管患者使用iNO后48小时内FiO2需求、P/F比值和呼吸频率均改善。
- iNO使用与住院时间、ICU停留时间、通气时间延长及肌酐升高发生率增加相关。
适用人群与场景
- 纳入2020年3月至2022年6月Mayo Clinic各院区SCCM VIRUS COVID-19登记库中需要HFNC、NIV或IMV的COVID-19患者。
- 自主呼吸组:保持未插管或在插管前启动HFNC(±NIV)的患者。
- 插管组:未预先使用HFNC(±NIV)即接受插管的患者。
研究设计与关键结果
- 多中心回顾性研究,纳入2767例患者,自主呼吸组1879例(153例接受iNO),插管组888例(193例接受iNO)。
- 采用倾向评分匹配(PSM)和逆倾向治疗加权(IPTW)分析结局。
- 自主呼吸组使用iNO后48小时内FiO2需求、P/F比值和呼吸频率改善;插管组同样改善。
- 自主呼吸组使用iNO未显著改变插管风险:PSM OR 1.08(CI 0.71-1.65);IPTW OR 1.10(CI 0.90-1.33)。
- 自主呼吸组使用iNO的院内死亡风险降低:PSM HR 0.49(CI 0.32-0.75);IPTW HR 0.40(95%CI 0.26-0.62)。
- 插管组使用iNO未见院内死亡风险降低:PSM HR 0.90(CI 0.66-1.24);IPTW HR 0.98(95%CI 0.73-1.31)。
- iNO使用与住院时间、ICU停留时间、通气时间延长及肌酐升高发生率增加相关。
证据类型、等级与局限
- 证据类型:多中心回顾性研究(倾向评分匹配)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在需要HFNC/NIV的自主呼吸COVID-19患者中,使用iNO可能降低院内死亡风险,但需权衡住院时间、ICU停留时间、通气时间延长及肌酐升高发生率增加的风险。
- 插管COVID-19患者使用iNO未显示院内死亡获益,但可改善氧合参数。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The benefit of Inhaled nitric oxide (iNO) therapy in the setting of COVID-19-related ARDS is obscure. We performed a multicenter retrospective study to evaluate the impact of iNO on patients with COVID-19 who require respiratory support.
METHODS: This retrospective multicenter study included COVID-19 patients enrolled in the SCCM VIRUS COVID-19 registry who were admitted to different Mayo Clinic sites between March 2020 and June 2022 and required high-flow nasal cannula (HFNC), non-invasive ventilation (NIV), or invasive mechanical ventilation (IMV). Patients were included in the 'spontaneously breathing' group if they remained non-intubated or were initiated on an HFNC (± NIV) before intubation. Patients who got intubated without prior use of an HFNC (± NIV) were included in the 'intubated group.' They were further divided into categories based on their iNO usage. Propensity score matching (PSM) and inverse propensity of treatment weighting (IPTW) were performed to examine outcomes.
RESULTS: Among 2767 patients included in our analysis, 1879 belonged to spontaneously breathing (153 received iNO), and 888 belonged to the intubated group (193 received iNO). There was a consistent improvement in FiO2 requirement, P/F ratio, and respiratory rate within 48 h of iNO use among both spontaneously breathing and intubated groups. However, there was no significant difference in intubation risk with iNO use among spontaneously breathing patients (PSM OR 1.08, CI 0.71-1.65; IPTW OR 1.10, CI 0.90-1.33). In a time-to-event analysis using Cox proportional hazard model, spontaneously breathing patients initiated on iNO had a lower hazard ratio of in-hospital mortality (PSM HR 0.49, CI 0.32-0.75, IPTW HR 0.40, 95% CI 0.26-0.62) but intubated patients did not (PSM HR: 0.90; CI 0.66-1.24, IPTW HR 0.98, 95% CI 0.73-1.31). iNO use was associated with longer in-hospital stays, ICU stays, ventilation duration, and a higher incidence of creatinine rise.
CONCLUSIONS: This retrospective propensity-score matched study showed that spontaneously breathing COVID-19 patients on HFNC/ NIV support had a decreased in-hospital mortality risk with iNO use in a time-to-event analysis. Both intubated and spontaneously breathing patients had improvement in oxygenation parameters with iNO therapy but were associated with longer in-hospital stays, ICU stays, ventilation duration, and higher incidence of creatinine rise.
参考来源
- Isha S, Balasubramanian P, Hanson AJ, et al. Impact of low dose inhaled nitric oxide treatment in spontaneously breathing and intubated COVID-19 patients: a retrospective propensity-matched study. Crit Care. 2024. PMID: 39456071. doi:10.1186/s13054-024-05093-w
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。